IonQ Unveils New Enterprise-Grade Quantum OS and Hybrid Services Suite
2.12.2024 22:05:00 CET | Business Wire | Press release
Full stack development approach drives enterprise-grade capabilities, enabling improved quantum functionality for commercial applicationsIonQ Quantum OS drives an average reduction of over 50 percent in on-system classical overhead, improving time to solution for quantum workloads
IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the launch of its quantum operating system, now called IonQ Quantum OS, and a collection of new capabilities named IonQ Hybrid Services suite. These technologies will greatly advance performance and utility of quantum computing for enterprise customers.
IonQ Quantum OS is a nearly ground-up rewrite of IonQ’s original quantum operating system. Designed and built with a flexible and modular architecture, it is designed to scale and adapt with IonQ’s hybrid quantum computing ecosystem and power IonQ’s current and future flagship quantum computers, including IonQ Forte and IonQ Forte Enterprise.
Designed for improved performance, IonQ Quantum OS dramatically improves time-to-solution, including:
- An average reduction of over 50 percent in on-system classical overhead (compared to identical workloads run on IonQ Forte before the improvements were deployed).
- An 85 percent reduction in cloud and network overhead of workloads submitted through the IonQ Cloud.
- Up to 100x improved accuracy in an expanded error mitigation and compilation suite.
- Enhanced calibration, automation, and control software and firmware to optimize qubit and gate performance and adjust for systemic drifts, resulting in better algorithmic performance.
IonQ Quantum OS also offers enterprise-grade security through improved observability and enhanced interoperability across on-premise hardware and software solutions. These improvements provide customers with new options for securely integrating quantum computing into their stack. IonQ Quantum OS has been running commercial workloads on IonQ Forte since summer 2024 and will soon be operational in controlling IonQ Forte Enterprise as it comes online in IonQ’s Basel, Switzerland data center.
“We designed our Quantum OS not only to address the complex demands of today’s enterprises but to scale seamlessly as their needs evolve,” said Peter Chapman, President and CEO of IonQ. “Our goal is to empower enterprise customers to unlock new possibilities and drive innovation with quantum computing.”
Showcased as an early preview with NVIDIA at SuperCompute 2024, IonQ’s new Hybrid Services suite is designed to enable seamless development and deployment of hybrid workloads that integrate IonQ quantum computers with high-performance classical resources over the cloud. This suite introduces significant advancements to enhance the speed, performance, and usability of quantum workloads, including:
- The Workload Management & Solver Service, a quantum developer toolkit that offers capabilities to efficiently move hybrid workloads to the cloud. This service features a quantum function and hybrid solver designed to help developers simplify the process of manually building circuits and iterative algorithms by packaging them into portable workloads to be executed and enhanced based on their needs.
- A new scheduling feature, Sessions, built on top of IonQ’s Fair Share scheduling engine, is designed to streamline provisioning of QPU time so that iterative and resource-intensive workflows run with minimal wait and interruption. Sessions also provides expanded support for offerings from IonQ’s cloud partners, including Amazon Braket Hybrid Jobs and Azure Quantum Sessions.
- The all-new IonQ SDK allows for seamless, simple, and reliable integration with IonQ Quantum Cloud API and IonQ Hybrid Services.
IonQ Hybrid Services suite is already accelerating the development of real-world, commercial quantum hybrid applications with customers. IonQ recently worked with Oak Ridge National Laboratory (ORNL) to implement a beta version of Hybrid Services to support the development of a NISQ-friendly quantum algorithm, which accelerates time-to-solution for hard optimization problems.
To learn more about IonQ and its latest system news and business developments, visit https://ionq.com.
About IonQ
IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.
IonQ Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words ”will,” “expect,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the expected benefits of IonQ’s quantum operating system and hybrid services suite, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, IonQ’s quantum computing capabilities and plans, the commercial relevance and advantages of applications, and the performance, scalability, accessibility, ease of use, capacity, power, speed, latency, quality, and reliability of IonQ’s quantum computing offerings. IonQ’s quantum computing capabilities and plans, improved efficiency and speed of quantum workloads and algorithms run on IonQ’s quantum computers, and the scalability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ’s ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, forecasts and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers; and events that may impact the security, quality and reliability of IonQ’s technology. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202941767/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom